Predictive factors for cytomegalovirus reactivation in cytomegalovirus‐seropositive kidney‐transplant patients
- 21 April 2008
- journal article
- research article
- Published by Wiley in Journal of Medical Virology
- Vol. 80 (6) , 1012-1017
- https://doi.org/10.1002/jmv.21176
Abstract
The aims of the present study were to assess the incidence of cytomegalovirus (CMV) reactivation, and to determine the predictive factors for CMV reactivation in CMV seropositive kidney‐transplant patients. One hundred ninety CMV seropositive kidney‐transplant patients were included in this study; of these, 39 patients had received CMV prophylaxis. CMV DNAemia was assessed by real‐timepolymerase chain reaction assay every 2 weeks until day 120, then every 3–4 weeks until day 180, and then every month until day 365. One hundred seven patients (56.3%) had at least one positive CMV DNAemia within the first year. The time between renal transplantation and the first positive CMV DNAemia was 59 ± 5 days. The number of positive CMV DNAemia/patient was 3.28 ± 0.22. CMV viral load at first positive CMV DNAemia was 704 (10–742,000) copies/ml. The donor CMV seropositivity, the absence of CMV prophylaxis, and the occurrence of acute rejection before CMV reactivation were independent factors associated with CMV reactivation within the first year after kidney transplantation. Hence, CMV reactivation is frequent after kidney transplantation. CMV prophylaxis in CMV seropositive kidney‐transplant patients should be offered to avoid CMV‐related side‐effects. J. Med. Virol. 80:1012–1017, 2008.Keywords
This publication has 19 references indexed in Scilit:
- Cytomegalovirus in transplantation – challenging thestatus quoClinical Transplantation, 2007
- Acute Rejection and Cardiac Allograft Vascular Disease Is Reduced by Suppression of Subclinical Cytomegalovirus InfectionTransplantation, 2006
- Reactivation of Viruses in Solid Organ Transplant Patients Receiving Cytomegalovirus ProphylaxisTransplantation, 2006
- Prophylactic Versus Preemptive Oral Valganciclovir for the Management of Cytomegalovirus Infection in Adult Renal Transplant RecipientsAmerican Journal of Transplantation, 2006
- Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantationBlood, 2006
- Cytomegalovirus Prophylaxis and Graft Outcome in Solid Organ Transplantation: A Collaborative Transplant Study ReportAmerican Journal of Transplantation, 2004
- Absence of Cytomegalovirus‐Resistance Mutations after Valganciclovir Prophylaxis, in a Prospective Multicenter Study of Solid‐Organ Transplant RecipientsThe Journal of Infectious Diseases, 2004
- Efficacy and Safety of Valganciclovir vs. Oral Ganciclovir for Prevention of Cytomegalovirus Disease in Solid Organ Transplant RecipientsAmerican Journal of Transplantation, 2004
- Automated Extraction and Quantification of Human Cytomegalovirus DNA in Whole Blood by Real-Time PCR AssayJournal of Clinical Microbiology, 2003
- Valacyclovir for the Prevention of Cytomegalovirus Disease after Renal TransplantationNew England Journal of Medicine, 1999